Stockscreener 앱 받기
8.851
4.80%
-0.449
전일 마감가:
$9.30
열려 있는:
$9.02
하루 거래량:
933.30K
Relative Volume:
0.50
시가총액:
$915.10M
수익:
-
순이익/손실:
$-135.21M
주가수익비율:
-6.1848
EPS:
-1.4311
순현금흐름:
$-114.35M
1주 성능:
-10.39%
1개월 성능:
-0.19%
6개월 성능:
-28.31%
1년 성능:
+88.37%
1일 변동 폭
$8.74
$9.06
1주일 범위
$8.74
$10.12
52주 변동 폭
$4.535
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.84 | 962.71M | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
427.29 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
784.56 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.42 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.17 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-11-20 | 개시 | Evercore ISI | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - ChartMill
Q2 EPS Estimate for Oric Pharmaceuticals Lowered by Analyst - MarketBeat
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $15 to $25 - Moomoo
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Citigroup Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $16.00 - MarketBeat
ORIC Pharmaceuticals Q1 2026 Financial Report and Forward-Looking Statements - Minichart
MSN Money - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.ORIC - ACCESS Newswire
ORIC Pharmaceuticals (NASDAQ: ORIC) lifts cash to $419.7M as R&D ramps - Stock Titan
Oric Pharmaceuticals (NASDAQ:ORIC) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ORIC (NASDAQ: ORIC) details Q1 2026 loss and Phase 3 cancer plans - Stock Titan
Cancer drug developer picks Phase 3 dose, has cash into late 2028 - Stock Titan
BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million - TradingView
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates - ChartMill
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Four new ORIC hires receive 216,000 options and 35,000 RSUs - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-01 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out | NDAQ:ORIC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewir - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC ... - Bluefield Daily Telegraph
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - FinancialContent
[ARS] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC Pharmaceuticals (NASDAQ: ORIC) 2026 proxy details equity plan changes, director elections, auditor - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmace - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Investors to Connect - ACCESS Newswire
Oric Pharmaceuticals (ORIC) to Release Earnings on Monday - MarketBeat
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ORIC falls after hours on safety concerns around prostate cancer candidate at higher doses - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Responsive Playbooks and the ORIC Inflection - Stock Traders Daily
A Look At ORIC Pharmaceuticals (ORIC) Valuation After New Rinzimetostat AACR Prostate Cancer Data - Sahm
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Stockholders to Connect - ACCESS Newswire
Oric Pharmaceuticals (ORIC) Stock Housing Data (Grinds Higher) 2026-04-20Retail Flow - Cổng thông tin điện tử Tỉnh Sơn La
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ORIC Pharma drops after early-stage trial data for prostate cancer therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-04-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ORIC | Press Release - Stockhouse
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting - Sahm
ORIC Highlights Rinzimetostat's Potential at Cancer Research Mee - GuruFocus
ORIC® Pharmaceuticals Presents Preclinical Data to Support - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceutical - The National Law Review
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 105% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oric Pharmaceuticals Inc 주식 (ORIC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Feb 24 '26 |
Sale |
13.51 |
52,000 |
702,686 |
68,148 |
5.78%
0.81%
자본화:
|
볼륨(24시간):